Clinical Trials

Peerless_RCT (Cardiology)

The purpose of this research is to compare how FlowTriever and CDT devices work when treating pulmonary embolism, and to collect data about your pulmonary embolism treatment and follow-up. There is nothing investigational or experimental in your medical treatment if you participate in this study.

Physician & Study Coordinator

Physician

Ellen Redstone, MD

Study Coordinators

Kyle McFadden
484-658-1803
kyle.mcfadden@sluhn.org

Synopsis

Eligibility Criteria

Age ≥ 18 years
Intervention planned to begin within 72 hours of the later of either: confirmed PE diagnosis; OR if transferring from another hospital, arrival at the treating hospital
Symptom onset within 14 days of confirmed PE diagnosis

Sanofi-Asthma ATLAS

A randomized, double-blind, placebo controlled study assessing the long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate to severe asthma

Physician & Study Coordinator

Physician

Mohamed Turki, MD

Study Coordinators

Margaret Clement
484-658-1799
Margaret.Clement@sluhn.org

Heather Herbold
484-658-1798
Heather.Herbold@sluhn.org

Synopsis

The purpose of the study is to learn more about dupilumab (the study drug) when given over a longer duration (3 years) in patients with moderate to severe asthma that is not well controlled.

Eligibility Criteria

At least 18
Patients with a physician diagnosis of asthma (according to Global Initiative for Asthma (GINA) 2021) for ≥12 months
Treatment with medium to high dose inhaled corticosteroids (ICS) (≥250 mcg of fluticasone propionate twice daily or equipotent ICS daily dosage to a maximum of 2000 mcg/day of fluticasone propionate or equivalent) in combination with a second controller (eg, long-acting beta-2 adrenergic receptor agonists (LABA), LTRA) with a stable dose ≥1 month

Sanofi-COPD_AERIFY

Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Physician & Study Coordinator

Physician

Mohamed Turki, MD

Study Coordinators

Margaret Clement
484-658-1799
Margaret.Clement@sluhn.org

Heather Herbold
484-658-1798
Heather.Herbold@sluhn.org

Synopsis

The purpose of the study is to investigate the effect, safety, and tolerability of the study drug for the treatment of patients with COPD, who continue to have symptoms on current treatment, and who are in need of additional treatment to their current COPD management.

Eligibility Criteria